1. Analysis of data to Advance Personalised Therapy with MR-Linac (ADAPT-MRL)
- Author
-
Jeremiah de Leon, Amanda Woods, Tania Twentyman, Michael Meade, Vicki Sproule, Smitha Chandran, Joseph Christiansen, Neil Kennedy, Maria Marney, Kris Barooshian, Michael Plit, Jayd Lynch, Raj Jagavkar, Helen Ormandy, John Christodouleas, Florian Pietzsch, Michael Chan, and Michael G Jameson
- Subjects
ADAPT-MRL ,Registry ,MR-Linac ,MRI ,Radiotherapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Analysis of Data to Advance Personalised Therapy with MR-Linac (ADAPT-MRL) is a multi-site, multinational, observational cohort registry designed to collect data on the use of the magnetic resonance linear accelerator (MR-Linac) for radiation therapy and patient outcomes. The registry will provide a linked repository of technical and clinical data that will form a platform for prospective studies and technology assessment. Methods: Design: This registry aims to include an estimated 10,000 eligible participants across Australia and other countries over a 7- to 10-year period. Participants will undergo treatment and assessments in accordance with standard practice. Toxicity and survival outcomes will be assessed at baseline, during treatment, and with 3 monthly follow-up until 24 months, patient reported outcome measures will also be collected. Participants with a variety of cancers will be included. Discussion: Data obtained from the ADAPT-MRL registry is expected to provide evidence on the safety and efficacy of the MR-Linac, a new technical innovation in radiation oncology. We expect this registry will generate data that will be used to optimise treatment techniques, MR-Linac software algorithms, evaluate participants’ outcomes and toxicities and to create a repository of adapted plans, anatomical and functional MR sequences linked to participants’ outcomes.
- Published
- 2021
- Full Text
- View/download PDF